Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids

Drug Safety

Volumn 27, Issue 9, 2004, Pages 649-660

  Allain, Hervé ^a   Ramelet, Albert A ^b   Polard, Elisabeth ^c   Bentué Ferrer, Danièle ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b Ctr Hosp Reg de Pontchaillou ^*

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOBESILATE CALCIUM;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANAPHYLAXIS; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ASTHENIA; CAPILLARY; CAPILLARY PERMEABILITY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPHAGIA; EDEMA; ERYTHEMA; ERYTHROCYTE AGGREGATION; EUPHORIA; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HEMORRHOID; HUMAN; LIVER INJURY; LYMPHATIC DRAINAGE; MALAISE; MALE; MEDICAL LITERATURE; MICROCIRCULATION; MYALGIA; NAUSEA; NONHUMAN; PAPULAR SKIN DISEASE; POSTMARKETING SURVEILLANCE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PUSTULE; RAT; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; URTICARIA; VEIN DISEASE; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT GAIN;

ANIMALS; CALCIUM DOBESILATE; CHRONIC DISEASE; CLINICAL TRIALS; DIABETIC RETINOPATHY; HEMORRHOIDS; HEMOSTATICS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; VENOUS INSUFFICIENCY;

EID: 3242760591     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427090-00003     Document Type: Review

References (91)

1. Le Dictionnaire Vidal: 81st ed. Paris; Vidal, 2003
2. Priollet P, Boisseau MR. Drugs for veno-lymphatic insufficiency. Rev Prat 2000; 50: 1195-8
3. Bouvenot G. Prescriptions and consumption of venotonic drugs in France (a propos of the report of the French National Institute for prescriptions and consumptions of drugs). Bull Acad Natl Med 1999; 183: 865-78
4. Ibanez L, Ballarin E, Vidal X, et al. Agranulocytosis associated with calcium dobesilate: clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 2000; 56: 763-7
5. Hobbs JT. Varicose veins. BMJ 1991; 303: 707-10
6. Wilson E. Prevention and treatment of venous leg ulcers [letter]. Health Trends 1989; 21: 97
7. Tran NT, Meissner MH. The epidemiology, pathophysiology and natural history of chronic venous disease. Semin Vasc Surg 2002; 15: 5-12
8. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management: summary of an evidence-based report of the VEINES task force: venous insufficiency epidemiologic and economic studies. Int Angiol 1999; 18: 83-102
9. Lamping DL. Measuring health-related quality of life in venous disease: practical and scientific considerations. Angiology 1997; 48: 51-7
10. Postmarketing Surveillance Study: calcium dobesilate, 1974-1998. Geneva: OM Pharma (Data on file)
11. Periodic Safety Update Reports: calcium dobesilate, 1 January 1995 to 31 January 2003. Geneva: OM Pharma (Data on file)
12. Baumelou E, Guiguet M, Mary JY, et al. Epidemiology of aplastic anemia in France: a case control study: I. medical history and medication use. Blood 1993; 81: 1471-8
13. Benichou C, Solal-Céligny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions: drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 1991; 33: 257-62
14. Böttiger LE, Furhoff AK, Holmberg L. Drug induced blood dyscrasias: a ten year material from the Swedish adverse drug reaction committee. Acta Med Scand 1979; 205: 457-61
15. Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 1996; 60: 23-30
16. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749-57
17. Mary JY, Guiguet M, Baumelou E. Drug use and aplastic anaemia: the French experience: French Cooperative Group for epidemiological study of aplastic anemia. Eur J Haematol 1996; 60: 35-41
18. Paitel JF, Stockemer V, Dorvaux V, et al. Agranulocytoses aiguës médicamenteuses: etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies. Rev Med Interne 1995; 16: 495-9
19. Rawson N, Rutledge-Harding S, Malcom E, et al. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 1998; 51: 1343-55
20. Van Der Klauw MM, Wilson JMP, Stricker BH. Drug associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am J Hematol 1998; 57: 206-11
21. Van Der Klauw MM, Goudsmit R, Halie E, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159: 369-74
22. Vial T, Profilet C, Pham E, et al. Agranulocytoses aiguës médicamenteuses: expérience du Centre Régional de Pharmacovigilance de Lyon sur 7 ans. Thérapie 1996; 51: 508-15
23. De Courten A. Doxium in capillary dysfunction. OM Digest 1979; 1: 1-7
24. Brunet J, Farine JC, Garay RP, et al. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205-12
25. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol 1997; 122: 1502-8
26. Falkay G, Kovacs L. Calcium dobesilate as a prostaglandin synthase inhibitor in pregnant human myometrium in vitro. Experientia 1984; 40: 190-1
27. McMillan DE, Utterback NG, Wajek JJ. Effect of anionic amphophiles on erythrocytes properties. Ann N Y Acad Sci 1983; 416: 633-41
28. Gloviczki P, Fowl RJ, Hollier LH, et al. Prevention of platelet deposition by ibuprofen and calcium dobesilate in expanded polytetrafluoroethylene vascular grafts. Am J Surg 1985; 150: 589-92
29. Michal M, Gotti C. Effect of calcium dobesilate on platelet function. Thromb Res 1988; 51: 593-605
30. Casley-Smith JR, Casley-Smith JR. The effects of calcium dobesilate on acute lymphedema (with and without macrophages) and on burn edema. Lymphology 1985; 18: 37-45
31. Casley-Smith JR. The influence of tissue hydrostatic pressure and protein concentration on fluid and protein uptake by diaphragmatic initial lymphatics; effect of calcium dobesilate. Microcirc Endothelium Lymphatics 1985; 2: 385-415
32. Piller NB. The lymphagogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology 1988; 21: 124-7
33. Van den Driessche J, Milon D, Saîag B. Pharmacology of the venous system. J Pharmacol 1986; 17 Suppl. 2: 5-29
34. Junger M, Steins A, Hahn M, et al. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 2000; 7 (6 Pt 2): S3-S12
35. Carpentier PH. Epidemiology and physiopathology of chronic venous leg diseases. Rev Prat 2000; 50: 1176-81
36. Gunnison AF, Jacobsen DW. Sulfite hypersensitivity: a critical review. CRC Crit Rev Toxicol 1987; 17: 185-214
37. Constantin D, Mehrotra K, Jernstrom B, et al. Alternative pathways of sulfite oxidation in human polymorphonuclear leukocytes. Pharmacol Toxicol 1994; 74: 136-40
38. Lester MR. Sulfite sensitivity: significance in human health. J Am Coll Nutr 1995; 14: 229-32
39. Anderson D, Yu TW, Philipps BJ, et al. The effect of various antioxidants and other modifying agents on oxygen-radical-generated DNA damage in human lymphocytes in the COMET assay. Mutat Res 1994; 307: 261-71
40. Graber R, Farine JC, Losa GA. Calcium dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis 1998; 3: 41-9
41. Sinzinger H, Rauscha F, Vinazzer H. Platelet function and prostaglandins in patients with peripheral vascular disease treated with calcium dobesilate. Prostaglandins Leukot Med 1987; 29: 1-9
42. Költringer P, Eber O, Rothlauer W, et al. Calcium dobesilate and its effects on hemorheology and microcirculation. Int J Clin Pharmacol Ther Toxicol 1988; 26: 500-2
43. Guerrini M, Pieragalli D, Acciavatti A, et al. Calcium dobesilate, hemorrheology, fibrinolysis and endothelium: new prospects in the prevention of diabetic microangiopathy: a study of clinical pharmacology. Clin Ter 1989; 129: 271-86
44. Ernst E, Marshall M. Improvement of reduced erythrocyte flexibility through calcium dobesilate: results of a pilot study. Münch Med Wochenschr 1984; 126: 125-6
45. Ehrly AM, Landgraf H, Saeger-Lorenz K. Therapy of intermittent claudication: influence of an oral administration of calcium dobesilate on oxygen partial pressure in muscle tissue. Therapiewoche 1986; 36: 3818-28
46. Heidrich H, Gerke E, Nekarda H. Inhibition of platelet aggregation under calcium dobesilate. Arzneimittel Forschung 1983; 33: 580-2
47. Pfliegler G, Boda Z, Udvardy M, et al. Effect of calcium dobesilate treatment on haemostasis and serum lipids in diabetic patients. Acta Ther 1986; 12: 71-9
48. Aimer LO, Pandolfi M, Nilsson IM. Diabetic retinopathy and fibrinolytic system. Diabetes 1975; 24: 529-34
49. Kappert A. Drug-therapy in functional capillary disorders. Z Ther 1974; 14: 71-89
50. Widmer L, Biland L, Barras JP. Doxium™ 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int Angiol 1990; 9: 105-10
51. Casley-Smith JR. A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology 1988; 39: 853-7
52. Mühleder J, Ohner W, Duma S. Perioperative treatment of patients with varicose veins using calcium dobesilate. Wien Med Wochenschr 1988; 138: 569-73
53. Pecchi S, De Franco V, Damiani P, et al. Calcium dobesilate in the treatment of chronic venous insufficiency of the lower limbs: a double-blind clinical trial. Clin Ter 1990; 132: 409-17
54. Leite EB, Mota MC, Faria De Abreu JR, et al. Effect of calcium dobesilate on the blood-retinal barrier. Int Ophthalmol 1990; 14: 81-8
55. Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991; 23: 12-20
56. Jaeger K, the CVI Study Group. Efficacy and safety of doxium in chronic venous insufficiency: double-blind, placebo-controlled multicentre study. Int Angiol 2001; 20 Suppl. 1: 239
57. Mentes BB, Görgül A, Tatlicioglu E, et al. Efficacy of calcium dobesilate in treating acute attacks of hemorrhoidal disease. Dis Colon Rectum 2001; 44: 1489-95
58. Sarabia M, Leon S, Vivas J, et al. Calcium dobesilate versus purified flavonoid fraction of diosmin in the treatment of hemorrhoidal crises: a randomized, controlled study with an initial double-blind, double period. Curr Ther Res 2001; 62: 524-9
59. Tamas P, Csermely T, Ertl T, et al. Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Gynecol Obstet Invest 1999; 47: 210-3
60. Andro G, Panoysis PA. Plethysmographic confirmation of the beneficial effect of calcium dobesilate in primary varicosis veins. Angiology 1989; 40: 1-4
61. Hachen HJ, Lorenz P. Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology 1982; 33: 480-8
62. Grignolo FM, Musso M, Borromeo P, et al. Fluorescence iris angiography in the assessment of calcium dobesilate therapy in the treatment of diabetic microangiopathy. Ophthalmologica 1979; 178: 250-8
63. Salama-Benarrroch I, Nano H, Perez H, et al. Assessment of calcium dobesilate in diabetic retinopathy: a double-blind clinical investigation. Ophthalmologica 1977; 174: 47-51
64. Van Bijsterveld OP, Janssen PT. Conservative therapy of diabetic retinopathy. In: Lerche W, editor. Diabetic retinopathy. Schattauer Verlag, Stuttgart, 1985, pp 43-52
65. Vinazzer H, Hachen HJ. Influence of calcium dobesilate on blood viscosity and coagulation parameters in diabetic retinopathy. VASA 1987; 16: 190-2
66. Jochens D, Stegmann W. Calcium dobesilate in the treatment of phlebopathies of the lower limbs: results from 80 medical pratices. Therapiewoche 1983; 33: 4559-62
67. Schmid K, Hase W. Geneva, OM Pharma, 1980 (Data on file)
68. Angehrn F. Efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency: an open-label, multicenter study. Curr Ther Res 1995; 56: 346-57
69. Arceo A, Berber A, Trevino C. Clinical evaluation of the efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency of the lower limbs. Angiology 2002; 53: 539-44
70. Vojnikovic B. Hyperviscosity of whole blood, plasma and aqueous humor decreased by doxium in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophth Res 1984; 16: 150-62
71. Benakis A, Glasson B, Bouvier CA, et al. Metabolism and pharmacokinetics of calcium dobesilate in man. Thérapie 1974; 29: 211-9
72. Kulessa W, Becker EW, Berg PA. Wiederholte Agranulozytose nach Einnahme von Calciumdobesilat. Dtsch Med Wochenschr 1992; 117: 372-4
73. Cladera Serra A, Blasco Mascaro I, Oliva Berini E, et al. Agranulocitosis inducida por dobesilato calcico. Med Clin (Barc) 1995; 105: 48-9
74. International Conference on Harmonisation. Guidance on Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs; Food and Drug Administration, HHS. Fed Regist 2004; 69: 5551-2
75. Garcia Benayas E, Garcia Diaz A, Ferez G. Calcium dobesilate-induced agranulocytosis. Pharm World Sci 1997; 19: 251-2
76. Doxium: compendium Suisse des medicaments. Basel; Documed, 2000: 745
77. Galindo Bonilla PA, Garcia-Rodriguez R, Feo Brito F, et al. Drug fever attributable to calcium dobesilate. Allergol Immunopathol (Madrid) 1996; 24: 19-21
78. Puyana J, Fraj J, De La Hoz F, et al. Drug-induced fever: a clinical report and challenge test with calcium dobesilate. Int Arch Allergy Appl Immunol 1990; 92: 364-5
79. Royo J, Canto G, Vives R, et al. Anaphylaxis due to calcium dobesilate [abstract]. Allergy 1998; 53 Suppl. 43: 103
80. Perez B, De Las Heras E, Hilara Y, et al. Acute generalized exanthematous pustulosis induced by calcium dobesilate. J Dermatol Treat 1994; 5: 211-3
81. Data on file. Geneva: OM Pharma, 2004
82. Krayenbuhl JC, Kondo-Oestreicher M, Sievering G, et al. Retrospective study of drug-induced agranulocytosis cases hospitalized in Geneva compared with cases notified to the IOCM. Schweiz Med Wochenschr 1998; 128: 199-202
83. Bäckström M, Hägg S, Mjörndal T, et al. Utilisation pattern of metamizole in northern sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf 2002; 11: 239-45
84. Anon. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986; 256: 1749-57
85. Zapater Hernandez P, Horga de la Parte JF, Garcia AG. Risk of drug-induced agranulocytosis: an approximation to risk analysis arising from spontaneous notification of agranulocytosis cases among patients treated with calcium dobesilate. An Med Interna 2002; 19: 275-82
86. Varonos DD, Santamouris S, Karambali S. The incidence of dipyrone-induced agranulocytosis in Greece during 1975. J Int Med Res 1979; 7: 564-8
87. Zapater P, Horga JF, Garcia A. Risk of drug-induced agranulocytosis: the case of calcium dobesilate. Eur J Clin Pharmacol 2003; 58: 767-72
88. Patton WN, Dufful SB. Idiosyncratic drug-induced haematological abnormalities. Drug Saf 1994; 11 (6): 445-62
89. Meng Z, Sang N, Zhang B. Effects of derivatives of sulfur dioxide on micronuclei formation in mouse bone marrow cells in vivo. Bull Environ Contam Toxicol 2002; 69: 257-64
90. Boada J, Nazco J. Clinical effectiveness of venotonic drugs: a meta-analysis. Methods Find Exp Clin Pharmacol 1996; 18 Suppl. B: 15-8
91. Bartolo M, Antignani PL. Drug therapy of venous insufficiency. Phlebologie 1985; 38: 353-7